Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00028626 · ClinicalTrials.gov registry record · Phase 2
Portal Vein Embolization in Treating Patients With Liver Metastases From Primary Colorectal Cancer
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00028626: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00028626 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00028626, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Embolization blocks blood flow to part of an organ and/or tumor. Blocking the portal vein on one side of the liver may cause the opposite side of the liver to increase in size and decrease the risk of liver failure following surgery. PURPOSE: Phase II trial to study the effectiveness of portal vein embolization in treating patients who have liver metastases from primary colorectal cancer.
Interventions
- DRUG embolization therapy
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-08 |
| Est. Completion | 2004-01 |
| Phase | Phase 2 |
What the finished NCT00028626 record still lists
NCT00028626 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which embolization therapy is the first listed.
NCT00028626 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00028626 about?
NCT00028626 is a clinical study titled "Portal Vein Embolization in Treating Patients With Liver Metastases From Primary Colorectal Cancer". RATIONALE: Embolization blocks blood flow to part of an organ and/or tumor. Blocking the portal vein on one side of the liver may cause the opposite side of the liver to increase in size and decrease the risk of liver failure following surgery. PURPOSE: Phase II trial to study the effectiveness of ...
What is the current status of trial NCT00028626?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-08. Estimated completion is 2004-01.
What interventions are being tested in trial NCT00028626?
The interventions under investigation include: embolization therapy (DRUG).
Who is sponsoring clinical trial NCT00028626?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia